Table 1.

Identified studies and their inclusion in the meta-analysis

YearAuthorEvaluable patientsDrugLine of treatmentInclusionQuality
1990Nicholson61TamoxifenFirst-lineNo*0
1992Wright65Tamoxifen or ovarian ablationFirst-lineYes0
1995Leitzel300Megestrol or fadrazoleSecond-lineNo2
1995Archer92Tamoxifen (64); goserelin (6); tamoxifen + goserelin (19); megestrol (3)First-lineYes1
1995Berns126Tamoxifen or othersFirst-lineYes1
1996Willsher52Tamoxifen (59); tamoxifen + goserelin (8)First-lineYes0
1997Yamauchi94DroloxifeneFirst-lineYes1
1998Elledge204TamoxifenFirst-lineYes2
1998Fehm23Not specifiedFirst-lineYes0
1999Houston241TamoxifenFirst-lineYes2
2000Bezwoda35TamoxifenFirst-lineNo0
2000Jukkola106Undefined HormonalFirst-lineYes1
2001Hayes103Megestrol (160, 800, or 1,600 mg/d)First-line and second-lineYes1
2002Lipton711Megestrol or fadrazole or letrozoleSecond-lineSecond-lineYes2
2003Lipton562Tamoxifen or letrozoleFirst-lineYes2
  • * The study by Wright is an update of this study.

  • The study by Lipton (2002) is an update of this study.